GCG and Alzheimer disease: We have reviewed the pharmacological effects of several GLP-1 Ras agonists on AD, including short-acting GLP-1 Ras, long-acting GLP-1 Ras, a GLP-1/Glucose-dependent insulinotropic polypeptide (GIP) Dual-Agonist, and a triple GLP-1/GIP/glucagon receptor agonist (TA).